Epidarex Capital, a transatlantic life science venture firm, has acquired Sirakoss by OssDsign, a Swedish medtech company, for an initial cash consideration of $11 million plus milestone and royalty payments.
Show CommentsClose Comments
Epidarex Capital, a transatlantic life science venture firm, has acquired Sirakoss by OssDsign, a Swedish medtech company, for an initial cash consideration of $11 million plus milestone and royalty payments.